Focused On-demand Library for Exosome complex component RRP45

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q06265

UPID:

EXOS9_HUMAN

Alternative names:

Autoantigen PM/Scl 1; Exosome component 9; P75 polymyositis-scleroderma overlap syndrome-associated autoantigen; Polymyositis/scleroderma autoantigen 1; Polymyositis/scleroderma autoantigen 75 kDa

Alternative UPACC:

Q06265; Q12883; Q4W5P5; Q86Y41; Q86Y48

Background:

Exosome complex component RRP45, also known as Exosome component 9, plays a crucial role in RNA processing and degradation. It is a non-catalytic component of the RNA exosome complex, involved in the maturation of stable RNA species and the elimination of RNA processing by-products. Its activities span both nuclear and cytoplasmic realms, facilitating the degradation of unstable mRNAs and participating in RNA surveillance pathways.

Therapeutic significance:

The protein's involvement in Pontocerebellar hypoplasia 1D, a severe neurologic disorder, underscores its therapeutic significance. Understanding the role of Exosome complex component RRP45 could open doors to potential therapeutic strategies for this and related disorders.